“Many patients with a rare disease suffer from a massive diagnostic delay. Our ambition is to shorten this way by raising disease awareness in cooperation with health care professionals and providing individual solutions to improve their life quality.”
“With specific cardiovascular expertise and highly innovative drugs, being able to improve clinical outcome of critically ill patients in acute and intensive care settings - that motivates me every day, together with committed colleagues, to achieve top performance in a renowned company.”
“As a an agile team we cumulate our knowledge, experience and hand-on approach to insure that the patients with rare diseases get a relieving treatment!”
“Have been working in hematology and oncology for more than twelve years, I have the wonderful chance to share these experiences with highly skilled and motivated colleagues at AOP Orphan for the benefit of Austrian patients. We work together to change patients lives in a positive way!”
“Our employees are the key to our success. With our highly selective products we can save lives at the crucial moment like in sepsis. This is my motivation.
Experienced team, courageous openness and mutual trust lead to good cooperation and set the standard for AOP Orphan Intensive Care!”
AOP Orphan is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.
Our motivation at AOP Orphan is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the Austrian health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases.
Austria occupies a special position among many countries where AOP Orphan is represented. In this market, the company began its development in 1996 and this is where AOP Orphan also has its broad and solid base with a head office. AOP Orphan Austria is a team of around twelve employees in the Marketing & Sales, and Medical for all three therapeutic divisions.
History of more than 20 years means many significant milestones — in research, social, business spheres and regulatory affairs — that were and are important for AOP Orphan.
Thanks to many years of experience in the provision of complex and individualized treatments, AOP Orphan gained special expertise and market presence in the field of rare diseases.
Since its very start AOP Orphan has borne the social responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases. We at AOP Orphan conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Orphan corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researches, physicians, therapists, caregivers, patient organizations and other stakeholders.
AOP Orphan is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.
From its inception AOP Orphan's culture is shaped by the entrepreneurial spirit of its founder. We are proud to be a company that encourages employees to come up with new ideas and to show ownership and initiative every day. To help neglected patients with rare diseases is our key motivator. Through close interaction with the scientific community, care givers and partners we aim to provide therapies and help patients beyond just providing drugs.
Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Orphan’s therapy concepts as well.
Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.
Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.